This database contains 145 studies, archived under the term: "patients"
Click here to filter this large number of results.
Relapse risk after discontinuation of risperidone in Alzheimer’s disease
Devanand, D. P.,
Mintzer, Jacobo,
Schultz, Susan K.,
Andrews, Howard F.,
Sultzer, David L.,
de la Pena, Danilo,
Gupta, Sanjay,
Colon, Sylvia,
Schimming, Corbett,
Pelton, Gregory H.,
Levin, Bruce
Background: Among patients with Alzheimer’s disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.; Methods: Patients with Alzheimer’s disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a […]
Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease
Burstein, Aaron H,
Zhao, Qinying,
Ross, Joel,
Styren, Scot,
Landen, Jaren W.,
Ma, Wendy W.,
McCush, Fred,
Alvey, Christine,
Kupiec, James W.,
Bednar, Martin M.
Objective: Ponezumab (PF-04360365) is a humanized anti-amyloid beta (Aβ) monoclonal antibody designed for treatment of Alzheimer disease (AD). A single 2-hour intravenous infusion of 0.1 to 10 mg/kg was previously shown to be safe and well tolerated in subjects with mild to moderate AD, with measurable effects on plasma and cerebrospinal fluid Aβ. This phase […]
Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids
Blackburn, Daniel J.,
Krishnan, Kailash,
Fox, Lydia,
Ballard, Clive,
Burns, Alistair,
Ford, Gary A.,
Mant, Jonathan,
Passmore, Peter,
Pocock, Stuart,
Reckless, John,
Sprigg, Nikola,
Stewart, Rob,
Wardlaw, Joanna,
Bath, Philip M. W.
Background: Stroke is a common cause of cognitive impairment and dementia. However, effective strategies for reducing the risk of post-stroke dementia remain undefined. Potential strategies include intensive lowering of blood pressure and/or lipids.; Design: multi-centre prospective randomised open-label blinded-endpoint controlled partial-factorial phase IV trial in secondary and primary care.; Participants: 100 participants from 30 UK […]
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment
Bakker, Arnold,
Krauss, Gregory L.,
Albert, Marilyn S.,
Speck, Caroline L.,
Jones, Lauren R.,
Stark, Craig E.,
Yassa, Michael A.,
Bassett, Susan S.,
Shelton, Amy L.,
Gallagher, Michela
Elevated hippocampal activation is observed in conditions that confer risk for Alzheimer’s disease, including amnestic mild cognitive impairment (aMCI). Studies in relevant animal models have indicated that overactivity in selective hippocampal circuits contributes to cognitive impairment. Here, we tested the effect of reducing hippocampal activation in aMCI. Under placebo treatment, hippocampal activation in the dentate […]
Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer’s patients–an open-label trial
Kennelly, Sean,
Abdullah, Laila,
Kenny, Rose Anne,
Mathura, Venkat,
Luis, Cheryl A.,
Mouzon, Benoit,
Crawford, Fiona,
Mullan, Michael,
Lawlor, Brian
Background: Evidence suggests that dihydropyridine calcium channel blockers may be useful in preventing and treating Alzheimer’s disease (AD).; Objective: In an open-label trial of safety and tolerability of nilvadipine in patients with AD, we examined cognition and executive function over a short time period to determine an influence of nilvadipine on these outcomes.; Method: We […]
Is high oral dose L-arginine intake effective in leukoaraiosis? Preliminary data, study protocol and expert’s opinion
Calabro, Rocco Salvatore,
Gervasi, Giuseppe,
Baglieri, Annalisa,
Furnari, Anna,
Marino, Silvia,
Bramanti, Placido
Background: Leukoraraiosis is worldwide considered as a part of the normal aging process, although it is strongly associated with dementia and other disabilities. The pathogenesis of leukoaraiosis still has not been thoroughly acknowledged, even though chronic ischemia with consequent arteriolosclerosis probably due to endothelial dysfunction has been suggested. Treatment focuses on prevention of lesion formation […]
Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
Farlow, Martin,
Arnold, Steven E.,
van Dyck, Christopher H.,
Aisen, Paul S,
Snider, B. Joy,
Porsteinsson, Anton P.,
Friedrich, Stuart,
Dean, Robert A.,
Gonzales, Celedon,
Sethuraman, Gopalan,
Demattos, Ronald B.,
Mohs, Richard,
Paul, Steven M.,
Siemers, Eric R.
Objectives: To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of 12 weekly infusions of solanezumab, an anti-β-amyloid (Aβ) antibody, in patients with mild-to-moderate Alzheimer’s disease. Cognitive measures were also obtained.; Methods: In this phase 2, randomized, double-blind, placebo-controlled clinical trial, 52 patients with Alzheimer’s disease received placebo or antibody (100 mg every 4 weeks, 100 […]
Effectiveness of family meetings for family caregivers on delaying time to nursing home placement of dementia patients: a randomized trial
Joling, Karlijn J,
van Marwijk, Harm W.J.,
van der Horst, Henriëtte E,
Scheltens, Philip,
van de Ven, Peter M.,
Appels, Bregje A.,
van Hout, Hein P.J.
Background: Interventions relieving the burden of caregiving may postpone or prevent patient institutionalization. The objective of this study was to determine whether a family meetings intervention was superior to usual care in postponing nursing home placement of patients with dementia.; Methods: A randomized multicenter trial was conducted among 192 patients with a clinical diagnosis of […]